The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
BIOE · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
CBLL · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | BIOE | ANIP | PGNY | CBLL |
|---|---|---|---|---|
| Moat Score (0–100) | 61 (highest) | 61 (highest) | 61 (highest) | 61 (highest) |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 65 | 75 | 78 (highest) | 70 |
| Pricing power | 57 | 94 | 30 | 100 (highest) |
| Returns on capital | — | 14 | 58 (highest) | — |
| Balance-sheet safety | 99 | 57 | 100 (highest) | 28 |
| Capital discipline | 24 | 67 (highest) | 42 | 47 |
| Price vs. high estimate | No price data | 386% above high estimate | 313% above high estimate (largest discount to high estimate) | No price data |
| Market cap | $10.3M | $1.8B | $2.7B | $670.6M |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |